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ABSTRACT Reversal of antimicrobial resistance is an appealing and largely unex-
plored strategy in drug discovery. The objective of this study was to identify poten-
tial targets for “helper” drugs reversing cephem resistance in Escherichia coli strains
producing -lactamases. A CMY-2-encoding plasmid was transferred by conjugation
to seven isogenic deletion mutants exhibiting cephem hypersusceptibility. The effect
of each mutation was evaluated by comparing the MICs in the wild type and the
mutant harboring the same plasmid. Mutation of two genes encoding proteins in-
volved in cell wall biosynthesis, dapF and mrcB, restored susceptibility to cefoxitin
(FOX) and reduced the MICs of cefotaxime and ceftazidime, respectively, from the
resistant to the intermediate category according to clinical breakpoints. The same
mutants harboring a CTX-M-1-encoding plasmid fell into the intermediate or suscep-
tible category for all three drugs. Individual deletion of dapF and mrcB in a clinical
isolate of CTX-M-15-producing E. coli sequence type 131 (ST131) resulted in partial
reversal of ceftazidime and cefepime resistance but did not reduce MICs below sus-
ceptibility breakpoints. Growth curve analysis indicated no fitness cost in a ΔmrcB
mutant, whereas a ΔdapF mutant had a 3-fold longer lag phase than the wild type,
suggesting that drugs targeting DapF may display antimicrobial activity, in addition
to synergizing with selected cephems. DapF appeared to be a potential FOX helper
drug target candidate, since dapF inactivation resulted in synergistic potentiation
of FOX in the genetic backgrounds tested. The study showed that individual in-
activation of two nonessential genes involved in cell wall biogenesis potentiates
cephem activity according to drug- and strain-specific patterns.
KEYWORDS extended-spectrum -lactamase (ESBL), cephem resistance, helper drug
Resistance to cephems, a group of -lactam antibiotics including cephalosporins andcephamycins, is clinically important, as these antimicrobial agents, especially
oxyimino-cephalosporins, are commonly used in clinical practice, are easy to adminis-
ter, and have low toxicity (1). With treatment options limited to “last-resort” antimicro-
bial agents, mainly carbapenems (2), no adequate therapeutic options exist to face the
worldwide increase of infections caused by cephem-resistant Enterobacteriaceae pro-
ducing extended-spectrum -lactamase (ESBL) or AmpC -lactamase, which have a
considerable clinical and economic impact (3). There is an urgent need for new therapeutic
strategies to manage both community- and hospital-acquired infections caused by these
bacteria. One of the possible strategies is to suppress resistant subpopulations by combi-
nation therapy (4). This approach includes combinations with “helper” drugs designed to
enhance antimicrobial activity (5). -Lactamase inhibitors are a prominent example of
helper drugs used in clinical practice. Numerous inhibitors with novel mechanisms of
inhibition are currently being developed against -lactamase-producing strains that have
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resistance to traditional inhibitors, such as clavulanic acid, tazobactam, and sulbactam (6).
A new -lactam–-lactamase inhibitor combination, ceftazidime-avibactam, has re-
cently been approved for clinical use (7). Efflux pump inhibitors (EPIs) are another
example of helper drugs suppressing resistance mechanisms, but despite the numer-
ous EPIs described in the scientific literature (8), none of them has reached clinical
development, mainly due to toxicity. In addition to suppression of resistance, helper
drugs can also reduce the likelihood of resistance development during antimicrobial
therapy (9).
The antimicrobial susceptibility phenotype of a given bacterial species depends
on the concerted activities of several elements, which as a whole are known as the
intrinsic resistome (10, 11). The various components of the Escherichia coli intrinsic
resistome have been inferred by previous studies measuring the susceptibility and
fitness of in-frame gene deletion mutants in the presence of antimicrobial agents
(12, 13). Despite the potential of the intrinsic resistome to serve as a source for helper
drug targets, no studies have investigated whether inactivation of these genes restores
susceptibility in resistant strains by reducing the MIC below the clinical breakpoint. In
this study, we evaluated the helper drug target potential of 16 selected genes impor-
tant for intrinsic resistance to cephems in E. coli (12, 13). The effect of each gene
deletion on cephem activity was studied by comparing the MICs of the deletion mutant
and the wild type in different E. coli genetic backgrounds harboring plasmids encoding
clinically important ESBLs (CTX-M-1 and CTX-M-15) or AmpC -lactamase (CMY-2). We
identified two gene deletions, ΔdapF and ΔmrcB, that potentiate cephem activity
against -lactamase-producing strains in a drug-specific fashion.
RESULTS
Effects of gene deletions on acquired cephem resistance. The MICs of cefoxitin
(FOX) and cefotaxime (CTX) in the E. coli wild-type strain BW25113 and in the 16
derivative isogenic Keio mutants selected for this study are shown in Table 1. Based
upon the magnitude of the MIC change determined by each gene deletion relative to
the wild type, six and two gene deletions exhibited synergy with FOX and CTX,
respectively. One gene deletion (ΔsurA) had an antagonistic effect with FOX. Seven
gene deletions resulted in MIC reductions greater than 2-fold (Table 1), and their effects
were studied in the same genetic background (BW25113) containing a CMY-2-encoding
plasmid. As expected, the plasmid conferred resistance to ceftazidime (CAZ), CTX, and
FOX in BW25113 (Table 2). However, in the presence of the same plasmid, two
individual gene deletions (ΔmrcB and ΔdapF) reduced the MICs of FOX and CTX by
TABLE 1MICs of FOX and CTX in E. coli wild-type BW25113 and in 16 derivative isogenic Keio mutants
Drug
MICa (g/ml)
Wild type mrcB dacA ycfM ybgF dapF ycjU fis rimK rplA dksA bamB surA tolC acrA recA yciM
FOX 4 0.25 1 0.5 1 0.5 2 4 4 4 2 4 16b 1 2 2 8
CTX 0.031 0.016 0.016 0.031 0.031 0.008 0.016 0.031 0.031 0.031 0.008 0.016 0.031 0.016 0.016 0.031 0.031
aThe MICs of drugs for which individual gene deletion resulted in a synergistic effect (interaction index  0.25) are underlined.
bDeletion of surA had an antagonistic effect on FOX (interaction index  4).
TABLE 2MICs of FOX, CTX, and CAZ in wild-type BW25113 E. coli and derivative isogenic Keio mutants carrying a CMY-2-encoding
plasmid
Drug
MICa (g/ml)
Wild type mrcB dacA ycfM ybgF dapF dksA tolC
Susceptibility
breakpoint
Resistance
breakpoint
FOX 32 8 32 16 16 2 16 32 8 32
CTX 8 4 8 16 8 2 4 8 1 4
CAZ 32 8 32 32 32 32 16 32 4 16
aMICs equal to or below the CLSI susceptibility breakpoints for Enterobacteriaceae (37) are indicated in boldface. The MICs of drugs for which individual gene deletion
resulted in a synergistic effect (interaction index  0.25) are underlined.
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more than 2-fold compared to wild-type strain BW25113. Both deletions exhibited
synergistic interactions with FOX, while CAZ and CTX synergistic interactions were
limited to ΔmrcB and ΔdapF, respectively (Table 2). According to the CLSI breakpoints,
these two mutants were susceptible to FOX and fell into the intermediate category for
CAZ and CTX, respectively (Table 2). The effects of these two gene deletions were
further evaluated in the presence of a CTX-M-1-encoding plasmid to check whether the
effect of each gene deletion is restricted to the specific -lactamase type. The MICs in
both ΔdapF and ΔmrcB mutants harboring the CTX-M-1-encoding plasmid were 8- to
16-fold lower than in the wild-type strain containing the same plasmid (Table 3). CTX
resistance was completely reversed by deletion of dapF, while the mrcB deletion
resulted in only partial reversal of resistance to the cephalosporin. Both deletions
exhibited synergistic interactions with CAZ and FOX, although both the wild type and
the mutants producing CTX-M-1 fell into the susceptible category, according to the
CLSI breakpoints for the drugs (Table 3).
Based on the susceptibility results, dapF and mrcB were deleted in a clinical isolate
of CTX-M-15-producing E. coli sequence type 131 (ST131) (UR40) to determine if the
two individual gene deletions could potentiate cephems in this epidemic clone. Both
the wild type and the mutants producing CTX-M-15 were susceptible to FOX, according
to the CLSI breakpoints (Table 4). Complete and partial reversal of CAZ resistance was
observed in ΔdapF and ΔmrcB mutants, respectively. The two mutants fell into the
intermediate category for cefepime (FEP) but retained resistance to ceftriaxone (CRO)
and CTX, most likely because the wild-type strain displays very high MICs of these two
oxyimino-cephalosporins (MICs, 64 and 128 g/ml, respectively). Deletion of dapF
had a synergistic effect with all five tested cephems, whereas only synergy with FOX
was detected following mrcB deletion (Table 4).
Real-time growth analysis of E. coli ST131 wild type and mutants. Real-time
growth curve analysis was performed to generate information regarding the fitness of
ΔdapF and ΔmrcB mutants compared to the wild type and to assess how these gene
deletions affected growth in the presence of FOX. This cephamycin was selected
because it was the only cephem that exhibited synergy with both deletions (Table 4).
TABLE 3MICs of FOX, CTX, and CAZ in E. coli wild-type BW25113 and in two derivative
isogenic Keio mutants carrying a CTX-M-1-encoding plasmid (ΔdapF and ΔmrcB)
Cephem
MICa (g/ml)
Wild type mrcB dapF
Susceptibility
breakpoint
Resistance
breakpoint
FOX 4 0.5 0.5 8  32
CTX 16 2 1 1  4
CAZ 2 0.25 0.25 4  16
aMICs below the CLSI susceptibility breakpoints for Enterobacteriaceae (37) are indicated in boldface. The
MICs of drugs for which individual gene deletion resulted in a synergistic effect (interaction index  0.25)
are underlined.
TABLE 4MICs of CRO, CTX, CAZ, FOX, and FEP in a clinical isolate of E. coli ST131 (UR40)
harboring a CTX-M-15-encoding plasmid and in two derivative isogenic mutants (ΔdapF
and ΔmrcB)
Drug
MICa (g/ml)
Wild-type
UR40 mrcB dapF
Susceptibility
breakpoint
Resistance
breakpoint
CRO 128 128 64 1  4
CTX 64 64 32 1  4
CAZ 16 8 4 4  16
FOX 8 <2 <2 8  32
FEP 16 8 4 2  16
aMICs equal to or below the CLSI susceptibility breakpoints for Enterobacteriaceae (37) are indicated in
boldface. The MICs of drugs for which individual gene deletion resulted in a synergistic effect (interaction
index  0.25) are underlined.
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Analysis of the lag phase of the two mutants and the wild type in FOX-free medium
showed no effect of mrcB deletion on bacterial growth. However, ΔdapF displayed a
3-fold-longer lag phase than the wild type and the ΔmrcBmutant (Fig. 1A). As expected,
supplementation of the medium with 2 g/ml of FOX had no effect on the growth of
the wild type but inhibited growth of both mutants (Fig. 1B).
MrcB and DapF homology between Enterobacteriaceae and humans. Consider-
able homology in amino acid sequence (100% coverage and 87 to 99% identity relative
to the sequence in E. coli) was detected for both proteins between Enterobacteriaceae
species: Klebsiella pneumoniae (87% for MrcB and 95% for DapF), Salmonella enterica
(91% for MrcB and 96% for DapF), Shigella flexneri (99% for MrcB and 99% for DapF),
and Citrobacter freundii (93% for MrcB and 98% for DapF). In contrast, no human
homologues were identified for MrcB and DapF.
DISCUSSION
We employed a novel, straightforward approach to identify potential antimicrobial
helper drug targets in ESBL/AmpC-producing E. coli. This approach applied knowledge
generated from previous high-throughput drug-gene interaction profiling studies showing
that individual gene deletions can cause hypersusceptibility in wild-type E. coli (12, 13).
Here, the effects of such gene deletions on cephem susceptibility were studied in resistant
E. coli producing different types of clinically important -lactamases. Interestingly, deletion
ofmrcB or dapF enhanced the activity of oxyimino-cephalosporins (CAZ, CTX, and FEP) and
cephamycins (FOX) according to drug- and strain-specific patterns. Complete reversal of
FIG 1 Growth curves of wild-type (WT) E. coli ST131 producing CTX-M-15 and derivative deletion mutants
(ΔdapF and ΔmrcB) in the absence (A) and presence (B) of 2 g/ml FOX.
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resistance, defined as a MIC reduction from the resistant to the susceptible category
according to clinical breakpoints, was observed only for FOX, by inactivation of either gene
in the CMY-2-producing strain (Table 2), and for CAZ, by dapF inactivation in the CTX-M-
15-producing strain (Table 4). Both gene products are involved in cell wall biogenesis, i.e.,
mrcB encodes a penicillin-binding protein (PBP1b) and dapF encodes an epimerase
involved in the synthesis of peptidoglycan precursors.
DapF appears to be a promising FOX helper drug target, since deletion mutants in
dapF displayed FOX potentiation and were consistently susceptible to the cephamycin
regardless of the strain genetic background and -lactamase type (Tables 2, 3, and 4).
Although the CTX-M-1 and CTX-M-15 -lactamases did not confer resistance in the
wild-type strain, dapF deletion mutants consistently showed MICs 6-fold lower than
that of the wild type, which is a desirable feature for a helper drug target. Deletion of
the gene also restored full susceptibility to CAZ in the CTX-M-15-producing strain (Table
4) but did not reduce the MIC of CAZ in the strain that produced CMY-2 (Table 2). We
do not know why the MIC of CAZ was not lowered in the presence of CMY-2, but this
observation suggests that combining CAZ with DapF inhibitors would not enhance CAZ
efficacy against strains expressing this AmpC type -lactamase. DapF, a cytoplasmic
diaminopimelate (DAP) epimerase, is part of the DAP pathway that converts diamin-
opimelic acid (LL-DAP) to a better peptidoglycan precursor (meso-DAP), which incor-
porates into the cell wall 1,000 times more efficiently than LL-DAP (14, 15). Deletion of
dapF increases the LL-DAP pool compared to meso-DAP, likely reducing the pepti-
doglycan synthesis rate, which in turn may explain the reduced fitness of the ΔdapF
ST131 mutant in the growth assay (Fig. 1). It should be noted that the increased
cephem susceptibility observed in this mutant may well be influenced by its reduced
fitness. The poor fitness of ΔdapF ST131 suggests that compounds interfering with
DapF function may exhibit a growth-inhibitory effect in vivo. The absence of DapF
homologues in mammals (15, 16) is another characteristic favorable for developing a
FOX helper drug targeting this protein.
Similar to ΔdapF, deletion of mrcB reversed FOX resistance in the CMY-2-producing
strain and increased susceptibility to both FOX and oxyimino-cephalosporins in the
CTX-M-producing strains (Tables 3 and 4). However, unlike ΔdapF, mrcB deletion
decreased the MIC of CAZ in the CMY-2-producing strain (Table 2) and did not affect
the strain’s fitness (Fig. 1). Previous studies have shown reduced fitness of ΔmrcB in
stationary-phase competition assays using model E. coli strains and decreased tolerance
for bile in Salmonella enterica serovar Typhi (17, 18). The mrcB gene product, PBP1b, is
one of the two major bifunctional penicillin-binding proteins in E. coli, with both
transglycosylase and transpeptidase enzymatic activities. PBP1b is uniquely important
for biofilm formation and motility and is implicated in outer membrane constriction
during cell division (19–21). While the enhanced cephem activity observed in ΔmrcB
could be due to reduced integrity of the peptidoglycan layer (22), the known synthetic
lethality between mrcB and mrcA (PBP1a) (20, 23–25) suggests a more specific mech-
anism. In particular, the potentiation of FOX in the ΔmrcB mutant implies that PBP1a
may be a primary target of the cephamycin. Interestingly, mrcA deletion did not cause
increased cephem sensitivity, suggesting a more critical role of PBP1b in cephem
resistance (12, 13, 23). PBP1b function requires interaction with the outer membrane
lipoprotein YcfM (20, 24, 26). In the absence of its interaction partner, aberrant YcfM
interactions with other proteins may introduce additional envelope stress in the
presence of cephems (20). These data suggest that lack of PBP1b-YcfM interaction not
only reduces peptidoglycan synthesis, but may also induce collateral damage in the
presence of cephems. It can be hypothesized that compounds interfering with PBP1b-
YcfM interaction may inhibit PBP1b functions and produce secondary deleterious
effects.
This study identified an antagonistic effect of surA deletion on FOX antimicrobial
activity but no interaction between the gene deletion and CTX in the CMY-2-
producing strain (Table 1). This observation suggests that the antimicrobial activity
of FOX partially depends upon SurA. This protein is a periplasmic chaperone that
Cephem Potentiation in Resistant Escherichia coli Antimicrobial Agents and Chemotherapy
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assists outer membrane porin maturation and outer membrane biogenesis (27).
Inactivation of surA results in fewer porins in the outer membrane and defects in
this membrane barrier (28, 29). The observed antagonism between surA deletion
and FOX may not be solely due to the reduced outer membrane porin-dependent
diffusion of FOX into the periplasmic space, since the activities of other cephems
were not affected in ΔsurA. Other, unknown factors, possibly related to SurA
chaperone functions, could be responsible for the increased MIC of FOX in this gene
deletion mutant.
In conclusion, this study identified two potential cephem helper drug target
candidates, DapF and PBP1b. Cephem activity was potentiated by inactivation of
the genes encoding these proteins, although full reversal of resistance was ob-
tained only for selected drugs and was generally influenced by the strain’s genetic
background and the -lactamase type, which may be regarded as undesirable
features for a novel helper drug. The only exception was dapF inactivation, which
synergistically potentiated FOX antimicrobial activity regardless of the strain’s genetic
background and -lactamase type. The reduced fitness of the ΔdapF mutant can be
regarded as a desirable feature, since drugs targeting DapF are likely to display their
own antimicrobial activity, in addition to synergizing with cephems. Moreover, the high
homology among Enterobacteriaceae and low similarity with human orthologues are
also favorable features for the helper drug target potential of DapF. On the basis of
these in vitro findings, more research is needed to assess the possible use of the protein
as a target for the discovery of helper drugs that enhance FOX activity when used in
combination.
MATERIALS AND METHODS
Antimicrobial agents and media. All the antimicrobial agents and growth media used in this study
were purchased from Sigma-Aldrich (Denmark) and Becton Dickinson (USA), respectively. Bacteria were
routinely grown on Luria-Bertani agar (LA) and in Luria-Bertani broth (LB). Susceptibility testing and
growth curve analysis were performed in cation-adjusted Mueller-Hinton Broth II (MHB II). SOC tryptone-
based medium (30) was used to enhance the recovery of transformants after electroporation. PCR
primers were synthesized by TAG (Copenhagen, Denmark).
Bacterial isolates and plasmids. Sixteen Keio mutants (31) and the wild-type E. coli K-12 (BW25113)
were purchased from the Coli Genetic Stock Center, Yale University (http://cgsc.biology.yale.edu/). These
mutants were selected based on the findings of two previous studies using the Keio collection (12, 13).
Our selection included (i) mutants that had reduced fitness (3-fold or greater) in the presence of different
cephems, such as cefaclor, cefoxitin, cefsulodin, and ceftazidime (ΔmrcB, ΔdacA, ΔycfM, ΔybgF, ΔdapF,
Δfis, ΔrplA, and ΔbamB) (13), and (ii) mutants that had increased susceptibility to 8 or more antimicrobial
agents, including at least one cephem (ΔybgF, ΔdapF, ΔycjU, ΔrimK, ΔrplA, ΔdksA, ΔsurA, ΔtolC, ΔacrA,
ΔrecA, and ΔyciM) (12). Donor strains carrying IncI1 plasmids encoding different -lactamases (CMY-2 and
CTX-M-1) were used for the conjugation experiments (32, 33) (Table 5). A representative of the epidemic
E. coli ST131 clone harboring blaCTX-M-15 on an IncF plasmid (strain UR40) (34) was used for genetic
engineering.
Transfer of -lactamase-encoding plasmids into Keio mutants. The well-characterized IncI1
CMY-2-encoding plasmid from E. coli R7AC (32, 35) was transferred individually into each selected
Keio mutant and the wild-type strain by conjugation and transformation, respectively. A second
IncI1 plasmid encoding CTX-M-1 (Table 5) was transferred by conjugation into two selected mutants,
ΔmrcB and ΔdapF. Briefly, 500 l of overnight donor and recipient cultures was centrifuged,
resuspended in 50 l LB, and incubated at 37°C. After 90 min of mating, the suspension was streaked
on a selective LA plate containing 25 g/ml kanamycin (Kan) and 1 g/ml CTX. Due to the lack of
a marker for counterselection, the same plasmids could not be introduced into the Keio wild-type
strain BW25113 by conjugation and thus were transformed by electroporation according to a
standard protocol (30). The wild-type transformants obtained were used as a reference to assess the
effects of each gene deletion in the Keio mutant transconjugants containing the same plasmid.
Targeted gene deletions in CTX-M-15-producing ST131. Two genes, mrcB and dapF, were deleted
individually in UR40 (ST131) using the -red recombination system (36). Briefly, a FLP recombination
target (FRT)-flanked chloramphenicol resistance cassette was amplified from a template plasmid,
pKD3, using primer pairs tagged with sequences containing 39 bases up- or downstream of the
target gene. As the UR40 strain was resistant to ampicillin (Amp) and Kan, a tetracycline resistance
(Tetr) marker was cloned into the original Amp resistance (Ampr) marker of the temperature-
sensitive helper plasmid, pKD46, carrying -red recombinase genes , , and exo under control of
an arabinose inducible promoter, araC-ParaB. The Tetr marker was PCR amplified from pBR322 using
primers containing 5= XmnI digestion sites and digested with XmnI (Thermo, USA). In parallel, pKD46
was digested with XmnI and subsequently dephosphorylated with alkaline phosphatase (Thermo,
USA). Finally, the two fractions were ligated using T4 DNA ligase (Thermo, USA), resulting in the
Baker et al. Antimicrobial Agents and Chemotherapy
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construction of pKD46 with the Tetr resistance marker. The newly constructed pKD46-Tetr plasmid
was transformed into the UR40 strain, and recombinase proteins were induced by adding arabinose
to the culture. Subsequently, the induced culture was used to prepare electrocompetent cells
following a standard protocol (30), and the amplified FRT-flanked resistance cassette was electro-
porated into the competent cells, followed by recovery in SOC medium and selection on LA plates
supplemented with 24 g/ml chloramphenicol. Finally, gene deletions were confirmed by PCR
amplification and sequencing (Macrogen Inc.). Primer sequences are available upon request.
Antimicrobial susceptibility testing. MICs of FOX, CTX, CAZ, CRO, and FEP were determined by
broth microdilution using two different types of commercial 96-well plates (ESB1F and COMPAN1F; Trek
Diagnostic Systems Inc.) according to the Clinical and Laboratory Standards Institute (CLSI) guidelines
(37). Each MIC value was reported as the average of at least two biological replicates. Complete reversal
of antimicrobial resistance was defined as a reduction of the MIC to equal to or below the CLSI
susceptibility breakpoint. Reduction of the MIC to the intermediate category was categorized as partial
reversal of resistance. To enable quantitative assessment of antibiotic–gene-deletion interaction, the
fractional inhibitory concentration index calculation (38) was modified to calculate the interaction index,
defined as follows: antibiotic MICmutant/antibiotic MICwild type. A stringent interpretation of interaction
index values of 0.25 and 4 was used to indicate synergistic and antagonistic interaction, respectively.
Values from 0.5 to 4 were considered “no interaction,” similar to the standard designations of
fractional inhibitory concentration index values (39). In addition, the synergistic and antagonistic
designations also correspond to a 4-fold minimum MIC decrease or increase, respectively, consistent with
interpretations in standard checkerboard assays (38).
Growth curve analyses. Growth curve analyses were performed using BioScreen (Oy Growth
Curves Ab Ltd., Finland). Broth microcultures of the mutants and the wild type in MHB II were
distributed into a 100-well plate with or without 2 g/ml FOX and incubated in a BioScreen chamber
for 18 to 24 h at 37°C under continuous shaking. The FOX concentration, 4-fold below the MIC of
the wild-type UR40 strain, was chosen based on the interaction index for synergy, 0.25. The optical
density at 600 nm (OD600) of each microculture was measured and recorded every 15 min, after a
standstill of 5 s in automatic mode. The recorded ODs were transferred to an Excel file and
subsequently used to plot growth curves.
In silico study of protein homology. The amino acid sequences of E. coli MrcB and DapF were
downloaded in FASTA format from Uniprot Web resources (http://www.uniprot.org) (uniprot entries
P02919 [MrcB] and P0A6K1 [DapF]) and were aligned with those of other Enterobacteriaceae (taxonomy
identification number [taxid], 91347) and human (taxid, 9606) homologues using protein BLAST on the
website of the National Center for Biotechnology Information (NCBI). Except for expansion of the
maximum target sequences, default BLAST parameters were used, with an expected cutoff value of 10.
The accession numbers used for the protein sequences were WP_016529988.1 (MrcB) and ACI11814.1
(DapF) for K. pneumoniae, WP_000918132.1 (MrcB) and WP_001160672.1 (DapF) for S. enterica,
EIQ27511.1 (MrcB) and EIQ17403.1 (DapF) for S. flexneri, and CAA90232.1 (MrcB) and WP_038634512.1
(DapF) for C. freundii.
TABLE 5 Bacterial strains and plasmids used in this study
Strain Plasmid -Lactamase enzyme Origin Relevant genotype or featuresa Reference
BW25113 Laboratory strain,
K-12 derivative
F Δ(araD-araB)567 ΔlacZ4787(::rrnB-3)  rph-1
Δ(rhaDrhaB)568 hsdR514
31
R7AC IncI1 CMY-2 Dog feces ST297 32
UR40 IncF CTX-M-15 Human urine ST131 34
2007-10-2348-1 IncI1 CTX-M-1 Cattle feces ST49 33
JW0145-1 BW25113 ΔmrcB::Kan 31
JW0627-1 BW25113 ΔdacA::Kan 31
JW5157-1 BW25113 ΔycfM::Kan 31
JW0732-1 BW25113 ΔybgF::Kan 31
JW5592-1 BW25113 ΔdapF::Kan 31
JW1310-1 BW25113 ΔycjU::Kan 31
JW0141-1 BW25113 ΔdksA::Kan 31
JW2496-3 BW25113 ΔbamB::Kan 31
JW0052-1 BW25113 ΔsurA::Kan 31
JW5503-1 BW25113 ΔtolC::Kan 31
JW0452-3 BW25113 ΔacrA::Kan 31
JW2669-1 BW25113 ΔrecA::Kan 31
JW0836-1 BW25113 ΔrimK::Kan 31
JW3947-1 BW25113 ΔrplA::Kan 31
JW1272-3 BW25113 ΔyciM::Kan 31
JW3229-1 BW25113 Δfis::Kan 31
pKD46-Ampr Synthetic plasmid -red genes (, , and exo) and araC-ParaB; Ampr 36
pKD46-Tetr Synthetic plasmid pKD46-Ampr derivative; Tetr This study
UR40 ΔdapF IncF CTX-M-15 UR40 (ST131) dapF::Cam This study
UR40 ΔmrcB IncF CTX-M-15 UR40 (ST131) mrcB::Cam This study
aAmp, ampicillin; Kan, kanamycin; Cam, chloramphenicol.
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